Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-c3 With Encorafenib and Cetuximab in Metastatic Colorectal Cancer
2022-502267-37-00Phase 2Completed
- Sponsor
- K-Group Beta, Inc.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of azenosertib in metastatic colon cancer (mCRC), sponsored by K-Group Beta, Inc. Primary endpoints: Dose escalation: Incidence of DLTs and Expansion cohort: Objective response rate (ORR). Started Jun 2023; status: completed.
02
Drugs
azenosertib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2022-502267-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502267-37-00.